baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cellectis SA/ US15117K1034 /

24/05/2024 21:59:09	Chg. -0.0799	Volume	Bid13:53:57	Ask13:53:57	High	Low
2.8200USD	-2.76%	17,668 Turnover: 43,855.5125	2.6800Bid Size: 2,000	2.8900Ask Size: 22,000	2.9126	2.7400

GlobeNewswire 27/05 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

GlobeNewswire 13/05 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire 09/05 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 06/05 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

GlobeNewswire 02/05 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

GlobeNewswire 29/04 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

GlobeNewswire 26/04 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...

GlobeNewswire 22/04 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...

GlobeNewswire 10/04 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...

GlobeNewswire 08/04 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and...

GlobeNewswire 14/03 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updat...

GlobeNewswire 16/01 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agre...

GlobeNewswire 04/01 Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro D...

GlobeNewswire 04/01 Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, ...

GlobeNewswire 22/12/2023 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

GlobeNewswire 09/12/2023 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-6...

GlobeNewswire 05/12/2023 Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actio...

GlobeNewswire 17/11/2023 Cellectis’ Shareholders Meeting to be Held on December 22, 2023

GlobeNewswire 15/11/2023 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

GlobeNewswire 06/11/2023 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

GlobeNewswire 03/11/2023 Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Target...

GlobeNewswire 03/11/2023 Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies a...

GlobeNewswire 02/11/2023 Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I ...

GlobeNewswire 02/11/2023 Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

GlobeNewswire 02/11/2023 Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Soci...

Cellectis SA/ US15117K1034 /

If you wish to receive reply to your feedback, please provide your email address.